Nantahala Capital Management’s Exagen XGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-61,186
Closed -$427K 178
2025
Q2
$427K Hold
61,186
0.02% 146
2025
Q1
$220K Sell
61,186
-930
-1% -$3.51K 0.01% 138
2024
Q4
$255K Hold
62,116
0.01% 130
2024
Q3
$192K Buy
62,116
+2,800
+5% +$7.25K 0.01% 130
2024
Q2
$108K Sell
59,316
-14,990
-20% -$25.4K 0.01% 124
2024
Q1
$118K Sell
74,306
-22,818
-23% -$44.3K 0.01% 117
2023
Q4
$193K Sell
97,124
-9,645
-9% -$16.7K 0.01% 121
2023
Q3
$258K Sell
106,769
-15,125
-12% -$38.4K 0.02% 117
2023
Q2
$353K Sell
121,894
-10,719
-8% -$30.5K 0.03% 105
2023
Q1
$322K Sell
132,613
-13,946
-10% -$36.1K 0.02% 112
2022
Q4
$352K Sell
146,559
-3,976
-3% -$10.2K 0.02% 103
2022
Q3
$408K Sell
150,535
-5,600
-4% -$31.2K 0.03% 101
2022
Q2
$896K Sell
156,135
-3,118
-2% -$18.2K 0.04% 101
2022
Q1
$1.28M Sell
159,253
-27,683
-15% -$239K 0.06% 98
2021
Q4
$2.17M Sell
186,936
-24,680
-12% -$289K 0.08% 105
2021
Q3
$2.88M Sell
211,616
-156,320
-42% -$2.08M 0.09% 96
2021
Q2
$5.51M Sell
367,936
-6,379
-2% -$97.8K 0.16% 88
2021
Q1
$6.55M Buy
+374,315
New +$6.67M 0.19% 76

Other funds holding XGN

Nantahala Capital Management's XGN Position: Q3 2025 in Review

Nantahala Capital Management sold out of Exagen (XGN) in Q3 2025, closing a stake of 61,186 shares — an estimated $427K sold.

Nantahala Capital Management first reported a position in XGN in Q1 2021 and held it in 18 quarters. The position peaked at $6.55M in Q1 2021. 62 funds tracked by Wall St. Rank hold XGN as of Q3 2025.

  • Nantahala Capital Management reported no remaining Exagen position as of Q3 2025 after selling out during the quarter.
  • Nantahala Capital Management sold 61,186 Exagen shares in Q3 2025, an estimated $427K.
  • Nantahala Capital Management first reported a position in Exagen in Q1 2021 and held it in 18 quarters.
  • Nantahala Capital Management's Exagen position peaked at $6.55M in Q1 2021.
  • 62 funds tracked by Wall St. Rank held Exagen as of Q3 2025.

Based on Nantahala Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.